172 related articles for article (PubMed ID: 31605337)
21. ASO Author Reflections: Current Status of Treatment of Peritoneal Carcinomatosis from Gastric Cancer Origin in Spain: Is It Possible to Cure These Patients?
Manzanedo I; Pereira F
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):792-793. PubMed ID: 31628556
[No Abstract] [Full Text] [Related]
22. ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis.
Baumgartner JM; Kurzrock R
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):772-773. PubMed ID: 30421042
[No Abstract] [Full Text] [Related]
23. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Reply.
Coleman RL
N Engl J Med; 2020 Feb; 382(7):686. PubMed ID: 32053314
[No Abstract] [Full Text] [Related]
24. ASO Author Reflections: Gastric Cancer with Peritoneal Metastasis: Are Some Patients Surgical Candidates?
Pimiento JM; Dineen SP
Ann Surg Oncol; 2021 Aug; 28(8):4138-4139. PubMed ID: 33866470
[No Abstract] [Full Text] [Related]
25. ASO Author Reflections: Long-Term Outcomes After R0 Resection of Colorectal Peritoneal Metastasis.
Shida D
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):832-833. PubMed ID: 30251024
[No Abstract] [Full Text] [Related]
26. ASO Author Reflections: Pathologic Classification of Pseudomyxoma Peritonei.
Baratti D
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):844-845. PubMed ID: 30324483
[No Abstract] [Full Text] [Related]
27. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
[TBL] [Abstract][Full Text] [Related]
28. Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge.
Azaïs H; Estevez JP; Foucher P; Kerbage Y; Mordon S; Collinet P
Surg Oncol; 2017 Mar; 26(1):46-52. PubMed ID: 28317584
[TBL] [Abstract][Full Text] [Related]
29. ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma.
Chouliaras K; Votanopoulos KI
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):770-771. PubMed ID: 30421064
[No Abstract] [Full Text] [Related]
30. ASO Author Reflections: Use of a National Database to Determine the Optimal Surgical Intervention for a Rare Appendiceal Cancer.
Nassour I; Kowalsky SJ
Ann Surg Oncol; 2021 Dec; 28(13):8926-8927. PubMed ID: 34159475
[No Abstract] [Full Text] [Related]
31. ASO Author Reflections: Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Lee ZJ; Teo CCM
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):757-758. PubMed ID: 30374919
[No Abstract] [Full Text] [Related]
32. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Shaalan W; Elemam D; Mansour H; Melis M; Malik E; Soliman AA
J Gynecol Oncol; 2018 Jul; 29(4):e47. PubMed ID: 29770618
[TBL] [Abstract][Full Text] [Related]
33. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
34. ASO Author Reflections: Real-World Incidence of Peritoneal Carcinomatosis After Colon Cancer Resection and Why It Matters.
Choi AH; Senthil M
Ann Surg Oncol; 2020 Dec; 27(13):4949. PubMed ID: 32627117
[No Abstract] [Full Text] [Related]
35. Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Sep; 35(9):5097-101. PubMed ID: 26254413
[TBL] [Abstract][Full Text] [Related]
36. ASO Author Reflections: The Peritoneum is an Active Immunological Compartment.
Thorgersen EB; Flatmark K
Ann Surg Oncol; 2021 Sep; 28(9):5263-5264. PubMed ID: 33939046
[No Abstract] [Full Text] [Related]
37. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
38. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
[TBL] [Abstract][Full Text] [Related]
39. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
40. Optimal cytoreduction with neutral argon plasma energy in selected patients with ovarian and primitive peritoneal cancer.
Renaud MC; Sebastianelli A
J Obstet Gynaecol Can; 2013 Jan; 35(1):49-52. PubMed ID: 23343797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
